Science

Study reveals Covid-19 symptoms that provide longer immunity from virus

Prashasti Awasthi Mumbai | Updated on January 13, 2021

Support previous studies that showed senior, male, and/or severely ill patients, have concentrations of antibodies, which is a key indicator of immunity

Researchers at the University of Wisconsin carried out a study to find specific symptoms of the novel coronavirus that indicate long and persistent immunity against the virus.

The study suggested that patients hospitalised with Covid-19 infection had higher antibody levels against the novel coronavirus than non-hospitalised patients.

Methodology

For the study, the researchers analysed blood tests from 113 patients infected with coronavirus five weeks after recovering from their illness. They again tested the patients three months after their infection.

Also read: Asymptomatic people drive over 50% of Covid-19 infection: CDC study

The researchers aimed to determine the concentration level of antibodies circulating in their systems at both intervals. The findings of the study were published in the pre-print server of medrxiv.org.

Results

For patients who weren’t hospitalised after getting infected with Covid-19, their symptoms led to varying levels of antibodies, with “cough, body aches, headache, nausea, and vomiting” only correlating to some antibodies present, while “chills, shortness of breath, chest tightness, sore throat, loss of taste or smell, and runny or stuffy nose” correlated to “no or almost (no)” antibodies.

The new findings support the previous studies that reported patients who are seniors, male, and/or those who fell severely ill have concentrations of antibodies, which is a key indicator of immunity.

Also read: Prepare for next pandemic by preserving animal specimens: Museum scientists

But the research also “demonstrated for the first time that (specific) Covid-19 symptoms…correlated consistently with higher anti-SARS-CoV-2 antibody levels” for at least three months.

Published on January 13, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor